← All trials
NCT05113641
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Nov 30, 2023
- Completion date
- Apr 30, 2024
- First posted
- Nov 9, 2021
- Last posted
- Nov 9, 2021
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of ManitobaLead sponsor
- Dalhousie UniversityCollaborator
- Government of CanadaOverall official - principal investigator
- Mount Saint Vincent UniversityCollaborator
- George and Fay Yee Centre for Healthcare InnovationOverall official - principal investigator
- Seven Oaks General Hospital Chronic Disease Innovation CentreOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.